Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

@article{Zuddas2011SecondGA,
  title={Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies},
  author={A. Zuddas and R. Zanni and T. Usala},
  journal={European Neuropsychopharmacology},
  year={2011},
  volume={21},
  pages={600-620}
}
In children and adolescents the Second Generation Antipsychotics (SGAs) represent the class of psychotropic drugs whose use has grown more significantly in recent years: they are primarily used for treatment of patients with disruptive behavior disorders, mood disorders and pervasive developmental disorders or mental retardation. In order to compare the efficacy and tolerability of antipsychotics against placebo or each other, a systematic Medline/PubMed search for randomized, double blind… Expand
Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.
Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
  • E. Kirino
  • Medicine
  • Adolescent health, medicine and therapeutics
  • 2014
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 140 REFERENCES
Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.
  • C. Correll
  • Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2008
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
...
1
2
3
4
5
...